{
    "name": "alglucosidase alfa",
    "comment": "Rx",
    "other_names": [
        "Lumizyme",
        "Myozyme"
    ],
    "classes": [
        "Enzymes",
        "Metabolic"
    ],
    "source": "https://reference.medscape.com/drug/lumizyme-myozyme-alglucosidase-alfa-342864",
    "pregnancy": {
        "common": [
            "Data from postmarketing reports and published case reports with alglucosidase alfa use in pregnant women have not identified an associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; the continuation of treatment during pregnancy should be individualized to pregnant woman; untreated disease may result in worsening disease symptoms in pregnant women",
            "Pregnant women and women of reproductive potential should be encouraged to enroll in the Pompe patient registry; the registry will monitor effect of therapy on pregnant women and their offspring; for more information, visit www.registrynxt.com or call 1-800-745-4447, extension 15500",
            "Disease-associated maternal and/or embryo-fetal risk; untreated Pompe disease has been associated with worsening respiratory and musculoskeletal symptoms in some pregnant women"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Reproduction studies performed in mice and rabbits at doses resulting in exposures up to 0.4 or  0.5 times the human steady-state AUC (area under the plasma concentration-time curve), respectively, during the period of organogenesis revealed no evidence of effects on embryo-fetal development; in mice there was an increase in pup mortality during lactation at maternal exposures 0.4 times the human steady-state AUC"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Available published literature suggests presence of alglucosidase alfa in human milk; there are no reports of adverse effects on the breastfed infant; there is no information on effects of alglucosidase alfa on milk production; developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal condition",
            "Lactating women with Pompe disease receiving treatment should be encouraged to enroll in Pompe disease registry",
            "A lactating woman may consider interrupting breastfeeding, pumping and discarding breast milk during treatment and for 24 hours after therapy administration in order to minimize drug exposure to a breastfed infant"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Anaphylaxis and severe hypersensitivity",
                    "description": [
                        "Life-threatening anaphylactic reactions and severe hypersensitivity reactions reported after IV infusions",
                        "Immune-mediated reactions presenting as proteinuria, nephrotic syndrome, and necrotizing skin lesions reported",
                        "Closely observe patients during and after administration and be prepared to manage anaphylaxis and hypersensitivity reactions",
                        "Inform patients and caregivers of the signs and symptoms of anaphylaxis, hypersensitivity reactions, and immune-mediated reactions and have them seek immediate medical care should signs and symptoms occur"
                    ]
                },
                {
                    "type": "Compromised cardiac or respiratory function",
                    "description": [
                        "Infantile-onset Pompe disease patients with compromised cardiac or respiratory function may be at risk of serious acute exacerbation of their cardiac or respiratory compromise due to fluid overload",
                        "Additional is monitoring required in these patients"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Anaphylaxis and hypersensitivity reactions have been observed in patients during and up to 3 hr after infusion; some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria Immune-mediated cutaneous reactions have been reported including necrotizing skin lesions; these reactions occurred several weeks to 3 yr after initiation",
                "Severe reactions are managed with infusion interruption, administration of antihistamines, corticosteroids, intravenous fluids, and/or oxygen, when clinically indicated; epinephrine may be administered; appropriate medical support, including cardiopulmonary resuscitation equipment, should be readily available when alglucosidase alfa is administered",
                "Consider risks and benefits of re-administering alglucosidase alfa following anaphylactic or hypersensitivity reaction; monitor closely with appropriate resuscitation measures available, if decision is made to re-administer product",
                "Nephrotic syndrome secondary to membranous glomerulonephritis was observed in some Pompe disease patients treated with alglucosidase alfa who had persistently positive anti-rhGAA IgG antibody titers; patients receiving alglucosidase alfa should undergo periodic urinalysis",
                "Patients with acute underlying respiratory illness or compromised cardiac and/or respiratory function may be at risk of serious exacerbation of their cardiac or respiratory compromise during infusions",
                "General anesthesia can be complicated by the presence of severe cardiac and skeletal (including respiratory) muscle weakness; extreme caution should be used when administering general anesthesia; ventricular arrhythmias and bradycardia, resulting in cardiac arrest or death, or requiring cardiac resuscitation or defibrillation have been observed in patients with infantile-onset Pompe disease with cardiac hypertrophy during general anesthesia for central venous catheter placement",
                "As with all therapeutic proteins, there is potential for immunogenicity; monitor patients for IgG antibody formation every 3 months for 2 years and annually thereafter; consider testing for IgG titers if patients develop hypersensitivity reactions, other immune-mediated reactions, or lose clinical response; may also test patients who experience reduced clinical response for inhibitory antibody activity; patients who experience anaphylactic or hypersensitivity reactions may also be tested for IgE antibodies to alglucosidase alfa and other mediators of anaphylaxis"
            ],
            "specific": [
                {
                    "type": "Immune Mediated Reactions",
                    "description": [
                        "Immune tolerance induction administered in conjunction with may also aid tolerability of alglucosidase alfa under management of a clinical specialist knowledgeable in immune tolerance induction in pediatric Pompe disease to optimize treatment",
                        "Immune tolerance induction administered prior to and in conjunction with initiation of alglucosidase alfa reported to aid tolerability of alglucosidase alfa in CRIM-negative patients; CRIM status has been shown to be associated with immunogenicity and patients’ responses to enzyme replacement therapies",
                        "CRIM-negative infants with infantile-onset Pompe disease treated with alglucosidase alfa have shown poorer clinical response in the presence of high sustained IgG antibody titers and positive inhibitory antibodies compared to CRIM-positive infants"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Pyrexia",
            "percent": "92"
        },
        {
            "name": "Diarrhea",
            "percent": "62"
        },
        {
            "name": "Rash",
            "percent": "54"
        },
        {
            "name": "Infusion reactions",
            "percent": "51"
        },
        {
            "name": "Vomiting",
            "percent": "49"
        },
        {
            "name": "Cough",
            "percent": "46"
        },
        {
            "name": "Diaper dermatitis",
            "percent": "46"
        },
        {
            "name": "Pneumonia",
            "percent": "46"
        },
        {
            "name": "Otitis media",
            "percent": "44"
        },
        {
            "name": "URI",
            "percent": "44"
        },
        {
            "name": "O",
            "percent": "2"
        },
        {
            "name": "saturation decreased",
            "percent": "41"
        },
        {
            "name": "Gastroenteritis",
            "percent": "41"
        },
        {
            "name": "Pharyngitis",
            "percent": "36"
        },
        {
            "name": "Respiratory distress",
            "percent": "33"
        },
        {
            "name": "Respiratory failure",
            "percent": "31"
        },
        {
            "name": "Anemia",
            "percent": "31"
        },
        {
            "name": "Oral candidiasis",
            "percent": "31"
        },
        {
            "name": "Rhinorrhea",
            "percent": "28"
        },
        {
            "name": "Catheter",
            "percent": "28"
        },
        {
            "name": "related infection",
            "percent": "26"
        },
        {
            "name": "GERD",
            "percent": "26"
        },
        {
            "name": "Post",
            "percent": "23"
        },
        {
            "name": "procedural pain",
            "percent": "23"
        },
        {
            "name": "Bronchiolitis",
            "percent": "23"
        },
        {
            "name": "Constipation",
            "percent": "23"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "23"
        },
        {
            "name": "Tachycardia",
            "percent": "21"
        },
        {
            "name": "Tachypnea",
            "percent": "21"
        },
        {
            "name": "Bradycardia",
            "percent": "21"
        },
        {
            "name": "Flushing",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "Bronchospasm",
            "percent": null
        },
        {
            "name": "Blurred vision",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Agitation",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Facial Erythema",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        },
        {
            "name": "Irritability",
            "percent": null
        },
        {
            "name": "Pallor",
            "percent": null
        },
        {
            "name": "Restlessness",
            "percent": null
        },
        {
            "name": "Tremor",
            "percent": null
        },
        {
            "name": "Vertigo",
            "percent": null
        },
        {
            "name": "Coronary artery disease",
            "percent": null
        },
        {
            "name": "Hypokalemia",
            "percent": null
        },
        {
            "name": "Conjunctivitis",
            "percent": null
        },
        {
            "name": "Anaphylactic shock",
            "percent": null
        },
        {
            "name": "respiratory failure",
            "percent": null
        },
        {
            "name": "respiratory arrest",
            "percent": null
        },
        {
            "name": "cardiac arrest",
            "percent": null
        },
        {
            "name": "hypoxia",
            "percent": null
        },
        {
            "name": "dyspnea",
            "percent": null
        },
        {
            "name": "wheezing",
            "percent": null
        },
        {
            "name": "convulsions",
            "percent": null
        },
        {
            "name": "peripheral coldness",
            "percent": null
        },
        {
            "name": "restlessness",
            "percent": null
        },
        {
            "name": "nervousness",
            "percent": null
        },
        {
            "name": "back pain",
            "percent": null
        },
        {
            "name": "stridor",
            "percent": null
        },
        {
            "name": "pharyngeal edema",
            "percent": null
        },
        {
            "name": "abdominal pain",
            "percent": null
        },
        {
            "name": "apnea",
            "percent": null
        },
        {
            "name": "muscle spasm",
            "percent": null
        },
        {
            "name": "conjunctivitis",
            "percent": null
        },
        {
            "name": "hyperparathyroidism",
            "percent": null
        },
        {
            "name": "Proteinuria and nephrotic syndrome secondary to membranous glomerulonephritis",
            "percent": null
        },
        {
            "name": "and necrotizing skin lesions reported",
            "percent": null
        }
    ]
}